![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » LILLY AND ALKERMES LAUNCH INSULIN STUDY
LILLY AND ALKERMES LAUNCH INSULIN STUDY
July 19, 2005
Alkermes and Eli Lilly announced the initiation of a Phase III trial required for registration for their inhaled insulin system, which is being investigated as an innovative treatment option for diabetes. The goal of this study is to more fully define the safety and efficacy of the Lilly/Alkermes inhaled insulin system in patients with diabetes.
This open-label, randomized study is designed to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in 400 non-smoking patients with Type 1 diabetes. Patients will be treated for 24 months with a two-month follow-up period.
A second multicenter, global safety study to support registration will begin in August. This Phase III open-label, randomized study is designed to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in 600 Type 1 and Type 2 diabetes patients with mild-to-moderate asthma or mild-to-moderate chronic obstructive lung disease. Patients will be treated for 12 months with a two-month follow-up period.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct